Eyenovia, Inc. (EYEN) financial statements (2021 and earlier)

Company profile

Business Address 295 MADISON AVENUE,
NEW YORK, NY 10017
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2814205
Cash and cash equivalents2814205
Prepaid expense0000
Deferred costs2  0
Other undisclosed current assets300(0)
Total current assets:3314205
Noncurrent Assets
Property, plant and equipment0000
Other undisclosed noncurrent assets0000
Total noncurrent assets:1000
TOTAL ASSETS:3415206
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3330
Accounts payable1220
Accrued liabilities0000
Employee-related liabilities111 
Interest and dividends payable0   
Deferred revenue14 
Debt0   
Deferred rent credit0  
Other undisclosed current liabilities1010
Total current liabilities:18331
Noncurrent Liabilities
Long-term debt and lease obligation0   
Long-term debt, excluding current maturities0   
Liabilities, other than long-term debt000 
Deferred rent credit000
Total noncurrent liabilities:000 
Total liabilities:19331
Stockholders' equity
Stockholders' equity attributable to parent, including:1512175
Common stock0000
Additional paid in capital93695324
Accumulated deficit(77)(58)(37)(19)
Other undisclosed stockholders' equity attributable to parent   0
Total stockholders' equity:1512175
TOTAL LIABILITIES AND EQUITY:3415206

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues2   
Cost of revenue(1)   
Gross profit:1   
Operating expenses(21)(21)(17)(5)
Operating loss:(20)(21)(17)(5)
Nonoperating income
(Investment Income, Nonoperating)
   0
Interest and debt expense(0)   
Net loss:(20)(21)(17)(5)
Other undisclosed net income attributable to parent000 
Net loss available to common stockholders, diluted:(20)(21)(17)(5)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(20)(21)(17)(5)
Comprehensive loss, net of tax, attributable to parent:(20)(21)(17)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: